Table 1.
Patient characteristics
| Age (range) | 52.8 (18.5–93.4) |
| Gender (female %) | 495 (80.9) |
| Smoking* (never %) | 132 (34.9) |
| Lung function follow-up length (years) | 8.2 (0.1–31.8) |
| Presence of ILD (%) | 394 (64.4) |
| Baseline pulmonary function* | |
| DLCO% predicted | 60.9 (47.9–74.4) |
| FEV1% predicted | 84.7 (71.9–96.0) |
| FVC% predicted | 88.7 (73.9–104.3) |
| CPI | 33.4 (22.9–45.9) |
| Mortality* (deaths %) | 250 (45.2) |
| Autoantibody* (%) | |
| ATA | 150 (26.5) |
| ACA | 126 (22.3) |
Number of patients is equal to 612 unless otherwise stated. Age is age at 1st pulmonary function test/1st hospital visit. Data are presented as age, mean (range), all other data are presented as median (interquartile range), except for follow-up length which is presented as median (range)
*smoking status available for n = 378, baseline pulmonary function available for n = 583, mortality available for n = 553 and autoantibody status available for n = 566
ILD interstitial lung disease, DLCO diffusing capacity of the lung for carbon monoxide, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, CPI composite physiological index, ATA anti-topoisomerase antibody, ACA anti-centromere antibody